Dupixent 300 MG/2 ML pen 2ML
Ended Awarded
- Contract number
- SPE2DB25FUQGA
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $33,465
Award facts
- Contract value 100% obligated
- $33,464.55 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,464.55 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors. This firm fixed price, non-set-aside contract was executed on September 8, 2025, with an ultimate completion date of September 9, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication indicated for multiple immune-mediated conditions, including moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, making it a critical pharmaceutical supply for military and federal healthcare systems.
This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999,999,999.00 global pharmaceutical support vehicle running through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen Drug Corp maintains an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies supporting military healthcare programs and the Defense Health Agency. The contractor's competitive performance across multiple therapeutic domains and consistent delivery of high-value pharmaceutical products demonstrates its capability to meet the DLA's demanding medical supply chain requirements.
Quick answers
Who was awarded contract SPE2DB25FUQGA?
SPE2DB25FUQGA was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on September 8, 2025.
How much is contract SPE2DB25FUQGA worth?
The government has obligated $33,465 on SPE2DB25FUQGA.
Is contract SPE2DB25FUQGA an order under another contract?
Yes. SPE2DB25FUQGA is a delivery order under SPE2DB25D3404, an indefinite delivery contract.
Was contract SPE2DB25FUQGA competed?
The extent of competition for SPE2DB25FUQGA was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award